[{"id":"beebcd86-9983-496c-baec-6ba92e35b0ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03003546","created_at":"2021-01-18T14:46:28.152Z","updated_at":"2024-07-02T16:35:45.549Z","phase":"Phase 1","brief_title":"Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial","source_id_and_acronym":"NCT03003546","lead_sponsor":"Mayo Clinic","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • albumin-bound paclitaxel • nab-paclitaxel/rituximab nanoparticle (AR160)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 04/25/2019","start_date":" 04/25/2019","primary_txt":" Primary completion: 05/16/2023","primary_completion_date":" 05/16/2023","study_txt":" Completion: 05/16/2023","study_completion_date":" 05/16/2023","last_update_posted":"2023-06-15"}]